详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Epigenetic mechanisms in non-small cell lung cancer therapy and chemoresistance

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sichuan, China [2]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China [3]Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074 Aachen, Germany

出处：

DOI：

ISSN：

关键词： Epigenetics Non-small cell lung cancer Chemoresistance Mechanism Molecular target

摘要：

Epigenetic mechanisms play a crucial role in cancer development and progression, encompassing DNA methylation, chromatin organization, histone modifications, and noncoding RNA regulation. Lung cancer is a major cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85 % of all cases. Despite advances in detection and treatment, the prognosis for NSCLC patients remains poor, largely attributable to the development of chemoresistance. Chemoresistance is a key driver of cancer recurrence and metastasis. Targeting epigenetic modifications emerges as a promising strategy to reverse chemoresistance. Elucidating the mechanisms by which epigenetic modulation influences chemoresistance in NSCLC, coupled with the development of drugs to counteract this phenomenon, offers significant potential to improve the survival rates and quality of life for NSCLC patients. In this review, we comprehensively summarize the contributions of various epigenetic regulators to chemoresistance in NSCLC. We also explore the relationship between distinct epigenetic modifications and chemoresistance in NSCLC and discuss the translational potential of these findings into clinical therapies.Copyright © 2025. Published by Elsevier B.V.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版中科院分区表Review为是的期刊

：

大类 | 2 区

医学

小类 | 2 区生化与分子生物学 2 区生物物理 2 区肿瘤学

最新[2025]版

：

大类 | 2 区

医学

小类 | 2 区生化与分子生物学 2 区生物物理 2 区肿瘤学

第一作者：

第一作者机构： [1]Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sichuan, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Heat Shock Proteins in Non-Small-Cell Lung Cancer-Functional Mechanism [2]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [3]KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review [4]Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer [5]ALK阳性非小细胞肺癌靶向治疗及其耐药机制的研究进展 [6]How Oncovirus Affects Drug Resistance in Cancer Cells [7]芒柄花素对人非小细胞肺癌细胞增殖、凋亡的影响及相关机制探讨 [8]Stress induces corticosterone-mediated CD8+ T cell exhaustion to promote non-small cell lung cancer [9]Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression [10]RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non-small cell lung cancer cells